G. Van

发表

T-cell co-stimulation through B7RP-1 and ICOS

T. Mak, T. Horan, G. Duncan, 1999, Nature.

Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts

T. Horan, R. Cattley, T. Kohno, 2003, International journal of cancer.

B-lymphocyte hyperplasia, and altered antibody production Transgenic overexpression of human IL-17E results in eosinophilia,

D. Danilenko, K. Clarkin, M. Stolina, 2013 .

Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production.

D. Danilenko, K. Clarkin, M. Stolina, 2002, Blood.

Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor.

D. Danilenko, G. Pierce, J. Tarpley, 1995, The American journal of pathology.

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

P. Kostenuik, S. Morony, W. Dougall, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteoprotegerin inhibits tumor‐induced osteoclastogenesis and bone tumor growth in osteopetrotic mice

D. Lacey, D. Clohisy, S. Scully, 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice

P. Kostenuik, S. Morony, M. Stolina, 2008, Circulation.

Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis.

D. Lacey, T. Ulich, J. Tarpley, 1996, The American journal of pathology.

Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function

R. Faggioni, T. Boone, S. McCabe, 2002, The Journal of Immunology.

Most purported antibodies to the human granulocyte colony-stimulating factor receptor are not specific.

A. Shehabeldin, S. Szilvassy, G. Van, 2010, Experimental hematology.

Myofibroblast and α1(III) collagen expression in experimental tubulointerstitial nephritis

Winson W. Tang, G. Van, M. Qi, 1997 .

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies

P. Kostenuik, M. Stolina, G. Schett, 2009, Arthritis research & therapy.

Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1

P. Kostenuik, I. Sarosi, M. Stolina, 2007, The Journal of Immunology.

Characterization of osteoclast precursors in human blood

D. Lacey, N. Hawkins, M. Kelley, 2000, British journal of haematology.

Leukemia inhibitory factor ameliorates experimental anti-GBM Ab glomerulonephritis.

G. Van, B. Samal, M. Qi, 1996, Kidney international.

Heparin attenuates bleomycin but not silica‐induced pulmonary fibrosis in mice: possible relationship with involvement of myofibroblasts in bleomycin, and fibroblasts in silica‐induced fibrosis

Jane Guo, P. Piguet, G. Van, 1996, International journal of experimental pathology.

Crescentic glomerulonephritis in CD4- and CD8-deficient mice. Requirement for CD4 but not CD8 cells.

P. Tipping, G. Van, M. Qi, 1998, The American journal of pathology.

A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage

T. Yokota, R. Nishinakamura, Chun Han, 2004, Development.

Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors

D. Lacey, M. Kelley, W. J. Boyle, 1999, Journal of cellular biochemistry.

Characterization of osteoclast precursors in human blood.

D. Lacey, N. Hawkins, M. Kelley, 2000 .

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

S. Morony, D. Lacey, D. Goeddel, 1999, Genes & development.

Chemokine expression in experimental tubulointerstitial nephritis.

J. Warren, Winson W. Tang, G. Van, 1997, Journal of immunology.

Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors

D. Lacey, V. Shalhoub, T. Burgess, 1999, Journal of cellular biochemistry.

Myofibroblast and alpha 1 (III) collagen expression in experimental tubulointerstitial nephritis.

G. Van, M. Qi, W. Tang, 1997, Kidney international.

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

S. Morony, D. Lacey, T. Mak, 1999, Nature.

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

G Shimamoto, D. Lacey, T. Boone, 1997, Cell.

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Josef M. Penninger, Brad Bolon, David L. Lacey, 1999, Nature.

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Josef M. Penninger, Brad Bolon, David L. Lacey, 1999, Nature.

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

D. Lacey, M. Kelley, W. J. Boyle, 1999, The Journal of cell biology.

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

D L Lacey, D. Lacey, M. Kelley, 2000, The American journal of pathology.

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

P. Kostenuik, S. Morony, D. Lacey, 2000, The Journal of experimental medicine.

Epo Receptors Are Not Detectable in Primary Human Tumor Tissue Samples

S. Elliott, J. Rossi, S. Scully, 2013, PloS one.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

D L Lacey, P. Kostenuik, S. Morony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

The Candidate Neuroprotective Agent Artemin Induces Autonomic Neural Dysplasia without Preventing Peripheral Nerve Dysfunction

T. Juan, B. Bolon, J. Tarpley, 2004, Toxicologic pathology.

Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.

K. Rex, A. Coxon, B. Bolon, 2002, Arthritis and rheumatism.

Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method

A. Coxon, J. Oliner, Marc Payton, 2014, Laboratory Investigation.

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

P. Kostenuik, S. Morony, D. Lacey, 2000, Cancer research.

Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.

M. Stolina, I. Pyrah, R. Boyce, 2015, Bone.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, Todd Juan, T. Bush, 2009, Molecular Cancer Therapeutics.

Combined Treatment of Acute EAE in Lewis Rats with TNF-Binding Protein and Interleukin-1 Receptor Antagonist

D. Danilenko, S. Ogenstad, L. Munyakazi, 1998, Experimental Neurology.

Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations.

N. Bucay, A. Thomason, W. S. Simonet, 1996, Oncogene.

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

P. Kostenuik, S. Morony, D. Lacey, 2000, The Journal of experimental medicine.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, T. Bush, R. Radinsky, 2009, Molecular Cancer Therapeutics.